Skip to main content
OpenTrials
Completed

NCT Number: NCT05813886

Evaluation of Dynamic Balance After Recovery From COVID 19 Disease

effect of post covid-19 on dynamic balance in patients after recovery from covid-19 disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–40 year

Sex eligibility

All sexes

Study type

Observational

Primary location

October 6 u

El-Sheikh Zayed City, Giza Governorate, 1133, Egypt

About this study

effect of post covid-19 on dynamic balance in patients after recovery from COVID disease.

patients will treated with medical protocol of COVID 19 an out-patient clinic , and followed up by the chest specialist . The balance tests of the patients were performed 2 to 14 weeks after their recovery from the disease, which was confirmed by the evaluations of the COVID staff and negative polymerase chain reaction test.the patients will evaluated using questionnaires. First, the question will whether feeling in balance in the daily life or not. The answer will classified as "yes"or "no". Second, asked to fill "Dizziness Handicap Inventory"(DHI), which is a multidimensional self- assessment scale created to evaluate the effects of dizziness and balance problems on the quality of life as well as the level of disability of the patients. Assess balance , which consists of a movable balance platform that provides up to 20 of surface tilt in a 360 range of motion. The platform is interfaced with computer software that enables the device to serve as an objective assessment of balance . The measure of postural stability includes the overall (OA), the anteroposterior (AP) and the mediolateral (ML) stability scores. A high score in the OA index indicates poor balance. The OA stability score is believed to be the best indicator of the overall ability of the patient to balance the platform

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 25post COVID-19 patients suffering from inbalance.
  • Age will be ranged from 30 to 40 years old.
  • Body mass index (BMI) will be ranged from 25 to 35 Kg/m2.
  • Diagnosed as COVID-19 patients with a positive reverse transcription polymerase chain reaction (RT-PCR) result of SARS-CoV-2, or typical computerized tomography (CT) evidence of viral pneumonia.
  • All enrolled patients with moderate covid-19 infection.

Exclusion criteria

  • Severe disease or hospitalization at intensive care units will excluded from the study.
  • Patients with previous hearing problems or balance disorders.
  • Patients who had ear surgery, cardiovascular and circulatory problems,.
  • Patients with orthopedic problems in the lower extremities due to other problems
  • Patients with Any history of neurological or psychiatric disease, severe visual or auditory impairments.
  • Diabetic patients.

Treatment and study plan

Biodex balance system

Other

The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.

Primary outcomes

  1. overall (OA), the anteroposterior (AP) and the Medio lateral (ML) stability scores

    Time frame: 2 to24 WEEKS after their recovery from the disease

    A high score in the OA index indicates poor balance. The OA stability score is believed to be the best indicator of the overall ability of the patient to balance the platform

Sponsors and collaborators

Lead sponsor

October 6 University

Other

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Apr 14, 2023
Registry last updated
Apr 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.